The Effect of Intrauterine Injection of Platelet-Rich Plasma on Pregnancy Outcomes in In-Vitro-Fertilization Candidates with Recurrent Implantation Failure

Abstract

Background: Platelet-rich plasma (PRP) contains over 20 growth factors and protein molecules that play a role in cell proliferation, differentiation, and regeneration. This study was designed to evaluate the impact of intrauterine PRP injection on women who have experienced recurrent implantation failure (RIF).

Methods: The present clinical trial involved 94 patients with RIF who were scheduled for in vitro fertilization (IVF). For the intervention (PRP) group, PRP was injected into the uterus using an intrauterine insemination catheter 24 to 48 hours before embryo transfer. The study then assessed and compared pregnancy rates between the intervention and control groups.

Results: This study found no significant baseline differences between the two groups. Endometrial thickness (ET) was comparable, measuring 7.50 ± 0.41 mm in the PRP group and 7.53 ± 0.56 mm in the control group. The PRP group exhibited significantly higher rates of both biochemical and clinical pregnancy. Specifically, the biochemical pregnancy rate was 64.6% (n = 39) in the PRP group compared to 19.6% (n = 9) in the control group (p < 0.001). Similarly, the clinical pregnancy rate was significantly higher in the PRP group at 50% (n = 24) versus 17.4% (n = 8) in the control group (p = 0.001).

Conclusion: The findings of this study reveal that the intrauterine injection of PRP prior to embryo transfer is a safe and affordable intervention that improves the pregnancy rate, with no major adverse effects observed.